[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease

Movement Disorders

Volumn 22, Issue 9, 2007, Pages 1278-1285

  Zijlmans, Jan ^a,b,c   Evans, Andrew ^a,b   Fontes, Flavia ^d   Katzenschlager, Regina ^a,b,e   Gacinovic, Svetoslav ^d   Lees, Andrew J ^a,b   Costa, Durval ^d,f  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c AMPHIA HOSPITAL   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Donauspital/ SMZ Ost ^*  (Austria)

^f HPP Medicina Molecular SA   (Portugal)

Author keywords

Criteria; FP CIT SPECT; L dopa challenge; Vascular parkinsonism

Indexed keywords

[(123 IODINE) 2 BETA CARBOXYMETHOXY 3 BETA ( 4 IODOPHENYL) N (3 FLUOROPROPYL) NORTROPANE]; BENSERAZIDE; CARBIDOPA; LEVODOPA; LIGAND; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; ANTIPARKINSON AGENT; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG BINDING; DRUG RESPONSE; FEMALE; HUMAN; MALE; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR DISEASE; VASCULAR LESION; VASCULAR PARKINSONISM; CORPUS STRIATUM; DRUG EFFECT; METABOLISM; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CORPUS STRIATUM; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 34548224682     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21479     Document Type: Article

References (41)

1. Tolosa ES, Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984;34:1516-1518.
2. Friedman A, Kang UJ, Tatemichi TK, Burke RE. A case of parkinsonism following striatal lacunar infarction [letter]. J Neurol Neurosurg Psychiatry 1986;49:1087-1088.
3. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord 1987;2:1-8.
4. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for a vascular etiology. Mov Disord 1989;4:249-260.
5. Zijlmans JCM, Thijssen HOM, Vogels OJM, et al. MRI in patients with suspected vascular parkinsonism. Neurology 1995;45:2183-2188.
6. Zijlmans JCM, Daniel SE, Hughes AJ, Revesz T, Lees AJ. A clinico-pathological investigation of vascular parkinsonism (VP), including clinical criteria for the diagnosis of VP. Mov Disord 2004; 2004;19:630-640.
7. Wichmann T, DeLong M. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6:751-758.
8. Booij J, Habraken JBA, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998; 39:1879-1884.
9. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-1508.
10. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15(4):692-698.
11. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62(2):133-140.
12. Katzenschlager R, Costa D, Gerschlager W, O'Sullivan J, Zijlmans J, Gacinovic S, Pirker W, Wills A, Bhatia K, Lees AJ, Brown P. [123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. Ann Neurol 2003;53(4):489-496.
13. Hughes AJ, Daniel SE, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
14. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987;153-163.
15. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:638-643.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychol Res 1975;12:189-198.
17. Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Mov Disord 2002;17(4):795-798.
18. Fearnley JM, Lees AJ. Aging and Parkinson's Disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
19. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28(4):547-555.
20. Forno L. Reaction of the substantia nigra to massive basal ganglia infarction. Acta Neuropathol (Berl) 1983;62:96-102.
21. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
22. Peters S, Eising EG, Przuntek H, Muller T. Vascular Parkinsonism: a case report and review of the literature. J Clin Neurosci 8(3): 268-271, 2001 May.
23. 18F] Fluorodopa Acta Neurol Scand 1996;93:387-392.
24. Remy P, de Recondo A, Defer G, et al. Peduncular 'rubral' tremor and dopaminergic denervation: a PET study. Neurology 1995;45:472-477.
25. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18(12):1415-1423.
26. Peralta C, Werner P, Holl B, Kiechl S, Willeit J, Seppi K, Wenning G, and Poewe W. Parkinsonism following striatal infarcts: Incidence in a prospective stroke unit cohort. J Neural Transm 2004;111:1473-1483.
27. Plotkin M, Amthauer H, Quill S, Marzinzik F, Klostermann F, Klaffke S, Kivi A, Gutberlet M, Felix R, Kupsch A. Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. J Neural Transm 2005;112:1355-1361.
28. Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45(10):1688-1693, 2004 Oct.
29. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 2001;42(3):408-413.
30. Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, Zijlmans JC, Hoffmann M, Brucke T. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17(3):518-523.
31. Chang CM, Yu YL, Ng HK, Leung SY, Fong KY. Vascular pseudoparkinsonism. Acta Neurol Scand 1992;86:588-592.
32. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
33. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand 2001;104:63-67.
34. Zijlmans JCM, Katzenschlager R, Daniel SE, Lees AJ. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 2004;75(4):545-547.
35. Leenders K, Salmon E, Turton D, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
36. Zijlmans JC, de Koster A, van't Hof MA, Thijssen HOM, Horstink MW, Heerschap A. Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism. Acta Neurol Scand 1994;90:405-411.
37. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/ PET. J Nucl Med 1996;37(11):1760-1765.
38. Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I] FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001;39(2):101-108.
39. Lavalaye J, Knol RJ, de Bruin K, Reneman L, Janssen AG, Booij J. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000; 27(3):346-349.
40. Critchley M. Arteriosclerotic parkinsonism. Brain 1929;52:23-83.
41. Fisher MC. Lacunes: small, deep cerebral infarcts. Neurology 1965;15:774-784.